SEATTLE, Aug. 14, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. ATOS, a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces financial results for the quarter ended June 30, 2023, and provides an update on recent…Read More
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update Atossa Therapeutics NASDAQATOS
